Carmignac Gestion Buys Shares of 9,014 Bristol Myers Squibb Company $BMY

Carmignac Gestion purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, Holdings Channel reports. The fund purchased 9,014 shares of the biopharmaceutical company’s stock, valued at approximately $519,000.

A number of other large investors have also modified their holdings of the company. California State Teachers Retirement System grew its holdings in Bristol Myers Squibb by 5,484.7% in the 2nd quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company’s stock worth $10,674,449,000 after buying an additional 181,938,762 shares in the last quarter. Norges Bank acquired a new position in Bristol Myers Squibb during the 4th quarter worth $1,947,272,000. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb in the second quarter worth $1,436,115,000. Legal & General Group Plc bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at about $980,862,000. Finally, AQR Capital Management LLC grew its position in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Down 3.3%

Shares of NYSE:BMY traded down $2.19 during trading on Tuesday, reaching $64.63. 9,522,716 shares of the company traded hands, compared to its average volume of 11,932,380. The firm has a fifty day simple moving average of $63.23 and a 200 day simple moving average of $60.00. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The firm has a market cap of $132.02 billion, a P/E ratio of 14.24, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the firm posted $1.46 earnings per share. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Analyst Ratings Changes

A number of equities analysts have issued reports on BMY shares. Sanford C. Bernstein raised Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 5th. Truist Financial restated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target on the stock. Finally, Royal Bank Of Canada raised their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.